{
    "id": 21414,
    "fullName": "ATRX R781*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ATRX R781* results in a premature truncation of the Atrx protein at amino acid 781 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R781* is predicted to lead to a loss of Atrx protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 546,
        "geneSymbol": "ATRX",
        "terms": [
            "ATRX",
            "JMS",
            "MRX52",
            "RAD54",
            "RAD54L",
            "XH2",
            "XNP",
            "ZNF-HX"
        ]
    },
    "variant": "R781*",
    "createDate": "04/19/2016",
    "updateDate": "04/19/2016",
    "referenceTranscriptCoordinates": {
        "id": 139984,
        "transcript": "NM_000489",
        "gDna": "chrX:g.77682915G>A",
        "cDna": "c.2341C>T",
        "protein": "p.R781*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20278,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Adavosertib (MK-1775) inhibited growth of patient-derived glioma cells harboring ATRX R781* in culture (PMID: 31551363).",
            "molecularProfile": {
                "id": 21929,
                "profileName": "ATRX R781*"
            },
            "therapy": {
                "id": 822,
                "therapyName": "Adavosertib",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17792,
                    "pubMedId": 31551363,
                    "title": "Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31551363"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21929,
            "profileName": "ATRX R781*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 139984,
            "transcript": "NM_000489",
            "gDna": "chrX:g.77682915G>A",
            "cDna": "c.2341C>T",
            "protein": "p.R781*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 139985,
            "transcript": "XM_006724668",
            "gDna": "chrX:g.77682915G>A",
            "cDna": "c.2341C>T",
            "protein": "p.R781*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}